2024-09-06 - Analysis Report
## GIS Stock Analysis Report

**Company Overview:** GIS is the ticker symbol for **Gilead Sciences, Inc.**, a biopharmaceutical company that develops, manufactures, and markets drugs for the treatment of life-threatening diseases like HIV, hepatitis B and C, and cancer.

**1. Performance Comparison:**

* **Cumulative Return:** GIS has a cumulative return of 49.5%, while the S&P 500 (VOO) has a cumulative return of 89.66%.
* **Relative Performance:** GIS has underperformed the S&P 500 by 40.16% (based on the cumulative return difference). This places it at the 17.64 percentile in terms of historical relative performance compared to the S&P 500. 

**2. Recent Price Movements:**

* **Closing Price:** $72.29
* **5-Day Moving Average:** $71.45
* **20-Day Moving Average:** $69.9
* **60-Day Moving Average:** $66.82

GIS is currently trading above its 5-day, 20-day, and 60-day moving averages, suggesting a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 75.94 - This indicates that the stock is currently in overbought territory. 
* **PPO:** 0.13 - A positive PPO value suggests a bullish momentum.
* **Delta_Previous_Relative_Divergence:** -3.57 - This negative value suggests a recent short-term decline in relative performance.
* **Expected Return:** 44.0% - This represents the potential 5-year return on investment based on current data.

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue       |
|------------|----------|---------------|
| 2024-06-26 | 0.98     | 4.71 B$      |
| 2024-03-20 | 1.18     | 5.10 B$      |
| 2024-06-26 | 1.18     | 5.10 B$      |
| 2023-12-20 | 1.03     | 5.14 B$      |
| 2024-06-26 | 1.03     | 5.14 B$      |

The most recent earnings report (2024-06-26) showed an EPS of $0.98 and revenue of $4.71 Billion. This falls slightly below the consensus estimate, which suggests that the market may be expecting stronger growth from GIS. It's important to note that these figures are just one data point and further analysis is needed to understand the underlying factors influencing GIS's performance.

**5. Overall Analysis:**

GIS has significantly underperformed the S&P 500 in the long term, but shows signs of a potential short-term upward trend. The stock is currently overbought and has experienced a recent decline in relative performance. However, the positive PPO value and high expected return signal potential bullish momentum. Further analysis is needed to assess the recent earnings and understand the long-term outlook for GIS. Investors should consider their own risk tolerance and investment goals before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and should not be considered financial advice.
